I understand, though also realise we’re the only company on the...

I understand, though also realise we’re the only company on the right path to product registration with although a step 1/phase 1 concluded only, a successful one, showing better tolerance and kinetics than Sativex, a massive competitor and the only other TGA registered product right now. Still risky, though probability tells me the least risk is in this company as so far we have what’s necessary to march on forward leaving many competitors behind.......... Even if we’re talking CBD only, unless the TGA makes drastic changes in the interim, companies will still need to do exactly what AusCann’s doing today to prove their products worth. The announcement says that this powder technology is better than oils and sprays. And we already know THC and CBD typically in a 1:1 ratio is effective for neuro pain. So expect the same results (positive) for future studies as this study, only that they need to be done! It’s a long road, though it’ll pay!

if the pharmacokinetics is there, which it is (and better), as will the effective results come IIA and III (if this is even required based on current literature available). Would be nice to see Neuvis registered by Christmas 21-22

DYOR